MDMB-FUBINACA

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
MDMB-FUBINACA
MDMB-FUBINACA.png
Systematic (IUPAC) name
methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
Clinical data
Legal status
Identifiers
CAS Number 1715016-77-5
ChemSpider 32741674
Chemical data
Formula C22H24FN3O3
Molecular mass 397.4 g/mol

MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1] Although there is no pharmacological information about MDMB-FUBINACA itself, its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (Ki = 0.14 nM, EC50 = 2.42nM).[2]

Side effects

There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold to date.[3] Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.[4][5][6]

Legal Status

As of October 2015 MDMB-FUBINACA is a controlled substance in Belarus, Russia,[7] and China.[8]

See also

References

  1. "MDMB-FUBINACA". Cayman Chemical. Retrieved 13 July 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
  3. Lua error in Module:Citation/CS1/Identifiers at line 47: attempt to index field 'wikibase' (a nil value).
  4. "25 killed, over 700 hospitalized: Cheap 'Spice' designer drug causes severe poisoning across Russia". 7 October 2014. Retrieved 13 July 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. "Выступление председателя ГАК, директора ФСКН России В.П. Иванова на заседании ГАК 6 октября 2014 г." Federal Drug Control Service of the Russian Federation. 6 October 2014. Retrieved 24 June 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. I. Bulygina (21 October 2014). "Clinical presentations of intoxication by new psychoactive compound MDMB(N)-Bz-F. Thesis of The II Scientific and Practical Seminar 'Methodical, Organizational and Law Problems of Chemical and Toxicological Laboratories of Narcological Services', Moscow". Retrieved 13 July 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Retrieved 13 July 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  8. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. <templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>